• Co-targeting BRD4 and RAC1 Disrupts the c-MYC-G9a Axis in Br

  2026-05-25

  This study presents a combinatorial strategy targeting BRD4 and RAC1 to suppress tumorigenic properties in breast cancer by disrupting the c-MYC-G9a-FTH1 signaling axis and downregulating HDAC1. The findings reveal new mechanistic insight into epigenetic regulation and offer a foundation for translational research using precise histone methyltransferase inhibitors.

• BX795: Advancing PDK1 Inhibition for Translational Oncology

  2026-05-24

  This thought-leadership article explores the mechanistic, methodological, and translational relevance of BX795—a potent, ATP-competitive PDK1 inhibitor—bridging the latest biological insights and strategic laboratory guidance. Integrating nuanced data from in vitro cancer drug response research, it delivers actionable recommendations for translational scientists seeking to deepen their understanding of PI3K/Akt/mTOR signaling, innate immune modulation, and the challenges of interpreting cell viability metrics. This article distinguishes itself by connecting advanced kinase inhibition with the evolving landscape of translational oncology and immune research, providing a roadmap for leveraging BX795 from APExBIO to its full experimental potential.

• BMX Kinase Drives Mtb Evasion via Host Lysosomal Acidificati

  2026-05-23

  This study uncovers a novel immune evasion mechanism by Mycobacterium tuberculosis (Mtb), demonstrating that Mtb-secreted Chp2 protein hijacks host BMX kinase to phosphorylate ATP6V1E1, thereby inhibiting lysosomal acidification and promoting intracellular survival. These findings highlight BMX kinase as a promising target for host-directed tuberculosis therapies.

• Dextran Sulfate Sodium Salt (MW 35000-45000): Advancing Inte

  2026-05-22

  Explore how Dextran sulfate sodium salt (MW 35000-45000) empowers translational ulcerative colitis research through advanced modeling of epithelial damage and repair. This in-depth analysis connects the latest GPR35-KLF5 findings to practical assay decisions, setting a new benchmark for intestinal inflammation studies.

• Pharmacokinetics of Corydalis saxicola Alkaloids in MASH Mod

  2026-05-22

  This study provides an integrated analysis of how metabolic dysfunction-associated steatohepatitis (MASH) alters the pharmacokinetics and tissue distribution of Corydalis saxicola Bunting total alkaloids. By pinpointing the impact of transporter and enzyme expression changes—especially P-glycoprotein and CYP450s—the findings offer valuable guidance for optimizing dosing regimens in liver disease settings.

• Intestinal TM6SF2 Deficiency Drives MASH via the Gut–Liver A

  2026-05-21

  This study uncovers the crucial role of intestinal TM6SF2 in protecting against metabolic dysfunction-associated steatohepatitis (MASH) by maintaining gut barrier integrity and modulating host–microbe interactions. Mechanistic insights reveal that TM6SF2 loss in intestinal epithelial cells leads to microbial dysbiosis, increased free fatty acid secretion, and lysophosphatidic acid (LPA)-mediated hepatic inflammation, highlighting potential therapeutic targets for MASH.

• Calcium Ions Modulate Amyloid Beta (1-40) Aggregation at Mem

  2026-05-21

  This study introduces supercritical angle Raman and fluorescence spectroscopy to directly observe the influence of calcium ions on amyloid beta (1-40) aggregation at lipid membranes. The findings clarify how Ca2+ modulates peptide-membrane interactions and amyloid fibril formation, which is crucial for understanding Alzheimer's disease pathogenesis and for the design of membrane-protective interventions.

• Vacuolin-1: Transforming Lysosomal Exocytosis in Disease Mod

  2026-05-20

  This thought-leadership article explores the mechanistic and translational impact of Vacuolin-1, a selective lysosomal exocytosis inhibitor, on dissecting the complexity of lysosome-driven diseases. Integrating evidence from recent cartilage pathology research, it provides both scientific rationale and actionable guidance for researchers seeking to leverage Vacuolin-1 in advanced disease modeling and membrane trafficking studies.

• Patient-Derived Gastric Cancer Assembloids Advance Targeted

  2026-05-20

  This study presents a rigorous methodology for generating gastric cancer assembloids by integrating matched tumor organoids with autologous stromal cell subpopulations. The resulting platform more faithfully recapitulates primary tumor heterogeneity, enabling nuanced investigation of drug responses and resistance relevant to personalized therapy development.

• 5-Azacytidine in Myeloma Models: Mechanistic Depth and Proto

  2026-05-19

  Explore the multifaceted actions of 5-Azacytidine in myeloma research, from ATR-mediated DNA damage to apoptosis induction. Discover unique protocol guidance and practical assay considerations for leveraging this DNA demethylation agent.

• Verbascoside: Applied PKC/NF-κB Inhibitor Workflows & Tips

  2026-05-19

  Verbascoside stands out as a precision PKC/NF-κB inhibitor, enabling robust modulation of osteoclastogenesis and inflammatory signaling in cell-based and translational research. This guide details practical workflow enhancements, troubleshooting strategies, and the latest assay-driven insights for maximizing Verbascoside’s research impact.

• 2-Hydroxypropyl-β-cyclodextrin: Technical Guide for Solubili

  2026-05-18

  2-Hydroxypropyl-β-cyclodextrin addresses the persistent challenge of formulating and solubilizing poorly water-soluble, hydrophobic research compounds—especially those containing aromatic or phenyl groups. It is intended for use as a solubility enhancer and drug formulation excipient in pharmaceutical and biochemical workflows. Broader or therapeutic applications, or uses outside solubility improvement, are not supported by current product specifications.

• LY294002 in Immunomodulation: Beyond Classic PI3K Inhibition

  2026-05-18

  Explore how LY294002, a potent PI3K/Akt/mTOR pathway inhibitor, is transforming immunomodulation research by enabling precise studies of macrophage polarization and tumor microenvironment dynamics. This cornerstone analysis provides advanced insights, protocol guidance, and a unique focus on PI3K-driven immune cell reprogramming.

• Thrombin: Optimizing Coagulation and Platelet Activation Ass

  2026-05-17

  Harness the precision of APExBIO's Thrombin B Chain Fragment to achieve high-fidelity modeling of the coagulation cascade, fibrin matrix formation, and platelet activation. This guide delivers actionable protocol enhancements and troubleshooting strategies, bridging cutting-edge vascular research with robust translational workflows.

• Phosbind Acrylamide (SKU F4002): Precision in Phosphorylatio

  2026-05-16

  This article addresses common laboratory challenges in protein phosphorylation analysis, highlighting how Phos binding reagent (Phosbind) acrylamide (SKU F4002) from APExBIO streamlines workflows and enhances reproducibility. By integrating scenario-driven Q&A blocks and literature-backed recommendations, we demonstrate why this phosphate-binding reagent is a reliable choice for SDS-PAGE phosphorylation detection.

451 records 17/31 page Previous Next First page 上5页 1617181920 下5页 Last page